October 18, 2018 Gaithersburg, MD -- VLP Therapeutics announced the issuance of US Patent 10,098,943 titled, “Flavivirus virus-like particle” on October 16, 2018. This patent supports VLP Therapeutics’ Native Virus Modification virus-like particle platform on
VLP Therapeutics is Recognized by the Government of Japan (Cabinet Office) “Comprehensive Strategy on Science, Technology and Innovation for 2017”
VLP Therapeutics was recently recognized as one of eleven companies that exemplify Japan’s commitment to Innovation as outlined in the 2017 Comprehensive Strategy on Science, Technology and Innovation. In 2017 the Cabinet Office of the
Patent covers a virus-like particle comprising a viral structural protein comprising modified envelope protein E3 Gaithersburg, Md. — May 18, 2018 — VLP Therapeutics, LLC. (“VLP”), a biotechnology company focusing on the research and development
“Structural studies of Chikungunya virus maturation” Moh Lan Yap, Thomas Klose, Akane Urakami, S. Saif Hasan, Wataru Akahata, and Michael G. Rossmann http://www.pnas.org/content/early/2017/11/29/1713166114.abstract?sid=89ef6c8b-994e-400d-af12-3726d0d40bbc
Vaccines are one of the most important inventions in the past centuries. The successful vaccines save millions of lives by eradicating the epidemic and pandemic diseases. I left the research field and formed VLP Therapeutics because I am committed to developing the next generation vaccine technology to treat the diseases that currently lack effective treatment. We believe that our i-αVLP vaccine technology has a potential to create a breakthrough treatments and make significant contributions to the improvement of global public health.